Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world effectiveness and safety of Siponimod (Mayzent) in Chinese adults with relapsing multiple sclerosis
CTR20230278Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of siponimod in multiple sclerosis (MS), clinically isolated syndrome (CIS), secondary-progressive multiple sclerosis (SPMS), sponsored by Novartis. Started Feb 2023; status: completed.
02
Drugs
siponimod
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on CTR20230278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230278.